Two new options for self-administration of Nucala now approved in Canada, making it the first anti-IL5 biologic to offer patients with severe eosinophilic asthma a choice of how and where to receive treatment


9 October 2019 - Nucala (mepolizumab) has been approved in Canada in two new formats – a pre-filled auto-injector and a pre-filled safety syringe – for use by health care professionals, patients and their caregivers. 

These new formats provide the option for patients to self-administer Nucala at-home, upon approval and training from their healthcare professional, for the treatment of severe eosinophilic asthma or eosinophilic granulomatosis with polyangiitis.

Nucala is the first anti-IL5 biologic to be licensed in Canada for at-home administration, and the first respiratory biologic to be approved for administration through an auto-injector.

Read GSK press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Canada